The metabolic syndrome, insulin resistance, and its surrogates in african and white subjects with type 2 diabetes in South Africa

Metabolic Syndrome and Related Disorders

Volumn 6, Issue 4, 2008, Pages 247-255

  Kalk, W J ^a,b   Joffe, B I ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SOUTH AFRICA; TRIGLYCERIDES;

EID: 57449109798     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0003     Document Type: Article

References (73)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S7-S84.
2. Mollentze WF, Moore A J, Steyn A F, Joubert G, Steyn K, Oosthuizen GM, et al. Coronary heart risk factors in a rural and urban Orange Freestate Black population. S Afr Med J 1995;85:90-96.
3. Levitt NS, Katzenallenbergen JM, Bradshw D, Hoffman MN, Bonnici F. The prevalence and risk factors for NIDDM in urban Africans in South Africa. Diabetes Care 1993;16:601-607.
4. Bradshaw D, Dorrington F, Sitas, F. The level of mortality in South Africa - what does it tell us about health? S Afr Med J 1993;92:238-241.
5. Kalk WJ, Joffe BI. Differences in coronary heart disease prevalence and risk factors in Africans and White patients with type 2 diabetes. Diab Res Clin Pract 2007;77:107-112.
6. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in African Americans. Heart Dis 2001;3:97-108.
7. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-46.
8. Lin SX, Pi-Sunyer FX. Prevalence of the metabolic syndrome among middle-aged and older adults with and without diabetes - a preliminary analysis of the NHANES 1999-2002 data. Ethn Dis 2007;17:35-39.
9. Tillin T, Forouhi N, Johnston DG, McKeigue PM, Chaturvedi N, Godsland IF. Metabolic syndrome and coronary heart disease in South Asians, Afro-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia 2005;48:649-656.
10. Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR. Insulin sensitivity at diagnosis of type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diab Med 2005;22:306-311.
11. Banerji MA, Lebovitz HE. Coronary heart disease risk factor profiles in black patients with non-insulin-dependent diabetes mellitus: paradoxic patterns. Am J Med 1991;91:51-58.
12. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, et al. Insulin resistance and acute insulin response in African-Americans, non-hispanic whites, and Hipanics with NIDDM. Diabetes 1997;46:63-69.
13. Joffe BI, Wing JR. Zouvanis M, Pierterse A, Seftel HC. NIDDM in African-Americans and black South Africans: many similarities but some important differences. Diabetes Care 1996;19:1451-1452.
14. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002;25:1135-1141.
15. Stoney RM, O'Dea K, Herbert KE, Dragicevic G, Giles GG, Cumpston GN, Best JD. Insulin resistance as a major determinant of increased coronary heart disease in postmenapausal women with type 2 diabetes mellitus. Diabetes Care 2001;18:476-482.
16. Sumner AE, Filey KB, Genovese DJ, MH Criqui, Boston RC. Fasting triglycerides and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005;165:1400-1595.
17. Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults. Executive Summary of the third report on the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
18. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [article online] (2005). Available from www.idf.org/webdata/docs/metabolic_syndrome_definition.pdf (accessed 17 May, 2005).
19. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-1062.
20. Stern MP, Williams K, Gonzalea-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and /or cardiovascular disease? Diabetes Care 2004;27: 2676-2681.
21. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabetic Med 2004;21:52-58.
22. Klein BEK, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002;25:1790-1794.
23. Costa LA, Canani LH, Lisboa RHK, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabetic Med 2004;21 252-255.
24. Ntyintyane LM, Panz VR, Raal FJ, Gill GV. Metabolic syndrome, undiagnosed diabetes mellitus and insulin resistance are highly prevalent in urbanised South African blacks with coronary artery disease. Cardivasc J S Afric 2006;17:50-55.
25. nd edition. Wits Diabetes Group, 1994.
26. rd edition. Wits Diabetes Group, 2000.
27. Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without the use of the preparative centrifuge. Clin Chem 1972,;18:499-502.
28. Kalk WJ, Joannou J, Ntsepo S, Mahomed I, Mahanlal P, Becker J. Ethnic differences in the clinical and laboratory associations with retinopathy: studies in patients of African, European and Indian origins. J Int Med 1997;241:31-37.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
30. th January, 2006).
31. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-809.
32. Reaven G, Tsoa PS. Insulin resistance and compensatory hyperinsulinaemia: the key player between cigarette smoking and cardiovascular disease? J Am Coll Cardiol 2003;41:1044-1047.
33. Dzien A, Dzien-Bischinger C, Hoppichler F, Lechleitner M. The metabolic syndrome as a link between smoking and cardiovascular disease. Diab Obesity Metab 2004;6:127-132.
34. Kalk WJ, Joffe BI. Low prevalence of the metabolic syndrome in diabetic African men by ATP III and IDF definitions: a study in African, white and south Asian men and women. Diabetologia 2006;49 (Suppl 1):236.
35. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants aged 50 years and older. Diabetes Care 2003;52:1210-1214.
36. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of the metabolic syndrome. Diabetes Care 2006;29:404-409.
37. Lee J, Ma D, Heng C-E, Tan S-K, Chew K, Highes K, Tain E-S. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care 2007;30:343-347.
38. Chen H-J, Pan W-H. Probable blind spot in the International Diabetes Federation definition of metabolic syndrome. Obesity 2007;15:1096-1100.
39. Kalk WJ: Is insulinopenia in African NIDDM important? Diabetologia 1997; 50:S112.
40. UK Prospective Diabetes Study Group. UK prospective diabetes study XII: differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetic Med 1994;11:670-677.
41. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P, for the Insulin resistance Atherosclerosis Study Investigators. Insulin sensitivity, insulinemia, and coronary heart disease. The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:781-787.
42. Gosland IF, Johnston DG, Chaturvedi N. Mechanisms of disease: lessons from ethnicity in the role of triglyceride metabolism in ischemic heart disease. Nat Clin Prac, Endocrinol Metab 2007;3:530-538.
43. Shires R, Joffe BI, Seftel HC. Hormonal and metabolic responses to an oral glucose load in obese black diabetics. S Afric Med J 1987;53:446-448.
44. van der Merwe M-T, Wing JR, Celgow LH, Gray IP, Lonn L, Joffe BI, Lonnroth PN. Metabolic indices in relation to body composition changes during weight loss on dexfenfluramine in obese women from two South African ethnic groups. Int J Obesity 1996;20:768-776.
45. Banerji MA, Chaiken RL, Gordon D, Lebovitz HE. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 1995;44:141-146.
46. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-2094.
47. Despres J-P, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. Race, visceral adipose tissue, plasma lipids and lipoprotein lipase activity in men and women. Arteriosclerosis Thrombosis Vasc Biol 2000;20:1932-1940.
48. Conway J, Yanovski S, Avila N, Hubbard V. Visceral and adipose tissue differences in black and white women. Am J Clin Nutr 1995;61:765-771.
49. Van der Merwe M-T, Panz,VR, Crowther NJ, Schlahoff GP, Gray IP, Froguel P, et al. Free fatty acids and insulin levels - relationship to leptin levels and body composition in various patient groups from South Africa. Int J Obesity 1999;23:909-917.
50. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetologia 2005;48:1679-1683.
51. Meigs JB, Fox CS, Rutter MK, D'Agostino RB, Sullivan LM, Wilson PWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2004;5:1219-1225.
52. Eberly LE, Prineas R, Cohen JD, Vaxquez G, Zhi X, Neaton JD, Kuller LH, for the Multiple Risk Factor Intervention Trial Research group. Metabolic syndrome. Risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial. Diabetes Care 2006;29:123-130.
53. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, on behalf of the INTERHEART study. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INERHEART study): a case-control study. Lancet 2004;364:937-952.
54. Hokanson JE, Austin M. Plasma triglyceride level is a risk factor for cardiovascular diseases independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based studies. J Cardiovasc Risk 1996;3:213-219.
55. Satoh A. Adachi H, Tsuruta M, Hiri Y, Hiratsuka A, Enomoto M, et al. High plasma levels of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care 2005;28:2514-2518.
56. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, et al. The metabolic syndrome, circulating oxidized LDL and risk of myocardial infarction in the Health, Aging and Body Composition Cohort Study. Diabetes 2004;53:1068-1073.
57. Ohkawara K, Tanaka s, Miyachi M, Ishikawa-Takata K, Tabata I. A dose-response relation between aerobic exercise and visceral fat reduction: a systematic review of clinical trials, Int J Obesity 2007;31:1786-1797.
58. Berentzen T, Petersen L, Pedersen O, Black E, Astrup A, Sorensen TIA. Long-term effects of leisure time physical activity on risk of insulin resistance and impaired glucose tolerance, allowing for body weight history, in Danish men. Diab Med 2007;24:63-72.
59. Perseghin G, Belloni E, Latuada G, Canu T, De Cobelli F, Terruzzi I, Ragogna F, Scifo P, Ntali G, Del Maschio A, Espoito A, Luzi L. Habitual phyical exercise is associated with intrahepatic fat content in humans. Diabetes Care 200;30:683-688.
60. Song Y, Buring JE, Manson JE, Liu SL. A prospective study of red meat consumption and type 2 diabetes in missle-aged and elderly women. Diabetes Care 2004;27:2108-2115.
61. De Mello VDG, Zelmanovitz T, Perossolo MS, Azevedo MJ, Gross JL. Withdrawal of red meat from usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria Am J Clin Nutr 2006;83:1032-1038.
62. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. Arterioscler Throm Vasc Biol 1999;9:972-978.
63. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracey RP, Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study. Circulation 2000;102:42-47.
64. Wannamethee SG, Lowe CDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease. Diabetologia 2004;47:1557-1565.
65. Hanley AJG, Bowden D, Wagenknecht LE, Langfeld C, Saad MF, Rotter JI, Guo X, Chen YI, Bryer-Ash M, Noris JM, Haffner SM. Associations of adiponectin and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endoceinol Metab 2007;92:2665-2671.
66. Considine RV, Premkumar A, Reynolds JC, Sebring NG, Ricks M, Sumner AE. Adiponectin and leptin in African Americans. Obesity 2008;16:428-434.
67. Van der Merwe M-T, Panz VR, Crowther NJ, Schlapoff GP, Gray IP, Froguel P, Joffe BI, Lonroth PN. Free fatty acids and insulin levels - relationship to Leptin levels and body composition in various patient groups from South Africa. Int J Obesity 1999;23:909-917.
68. Shikany JM, Lewis CE, Freedman BI, Arnett DK, Leiendecker C, Jones TL, Redden DT, Oberman A. Plasma adiponectin concentrations and correlates in African Americans in the Hypertension Genetic Epidemiology Network (HyperGEN) study. Metabolism, 2007;56:1011-1016.
69. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark Luther T, Hunningshake DB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of the recent clinical trials of the National Cholesterol Education Program Treatment Panel III guidelines. Circulation 2004;110:227-239.
70. Blackburn P, Lamarche B, Couillard C, Pascot A, Bergeron N, Prud'homme D, et al. Postprandial hyperlipemia: another correlate of the " hypertriglyceridemic waist" phenotype in men. Atherosclerosis 2003;171:327-336.
71. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
72. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A,Kazakos K, Yovos J, Bakris GL. Validity and reproducibility of HOMA-IR, I/HOMA-IR, QUIKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens 2007;21:709-716.
73. Joffe BI, Distiller LA, Kalk WJ. Lipid levels in black South Africans with type 2 diabetes: dispelling misconceptions. Diabetes Care 2004;27:1839-1840.